Cladribine is an approved drug for the treatment of highly active multiple sclerosis. We report a 28-years-old man with a poor response to previous treatments, elected to treatment with Cladribine. He developed a lichenoid rash two weeks after taking the first and second treatment cycles. This symptom regressed with specific therapy. A lichenoid drug eruption is a rare side effect which can occur following the administration of several different medications, but it has never been described after treatment with oral Cladribine.
Lichenoid rash: A new side effect of oral Cladribine / Aruta, F.; Iovino, A.; Costa, C.; Manganelli, F.; Iodice, R.. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 41:(2020), p. 102023. [10.1016/j.msard.2020.102023]
Lichenoid rash: A new side effect of oral Cladribine
Aruta F.;Iovino A.;Costa C.;Manganelli F.;Iodice R.
2020
Abstract
Cladribine is an approved drug for the treatment of highly active multiple sclerosis. We report a 28-years-old man with a poor response to previous treatments, elected to treatment with Cladribine. He developed a lichenoid rash two weeks after taking the first and second treatment cycles. This symptom regressed with specific therapy. A lichenoid drug eruption is a rare side effect which can occur following the administration of several different medications, but it has never been described after treatment with oral Cladribine.| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS2211034820300997.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
434.13 kB
Formato
Adobe PDF
|
434.13 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
